BG62977B1 - Вирусен материал и нуклеотидни фрагменти, свързани с диагностика, профилактика и лечение на мултиплената склероза - Google Patents

Вирусен материал и нуклеотидни фрагменти, свързани с диагностика, профилактика и лечение на мултиплената склероза Download PDF

Info

Publication number: BG62977B1
Authority: BG; Bulgaria
Prior art keywords: seq; sequence; sequences; nucleotide; msrv
Prior art date: 1995-08-03

Application number

BG101355A

Other languages

Bulgarian (bg)

English (en)

Other versions

BG101355A (en

Inventor

Herve Perron

Frederic Beseme

Frederic Bedin

Glaucia Paranhos-Baccala

Florence Komurian-Pradel

Colette Jolivet-Reynaud

Bernard Mandrand

Original Assignee

Bio Merieux

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-08-03

Filing date

1997-03-25

Publication date

2000-12-29

1997-03-25 Application filed by Bio Merieux filed Critical Bio Merieux

1997-12-30 Publication of BG101355A publication Critical patent/BG101355A/xx

2000-12-29 Publication of BG62977B1 publication Critical patent/BG62977B1/bg

Links

239000002773 nucleotide Substances 0.000 title claims abstract description 199
125000003729 nucleotide group Chemical group 0.000 title claims abstract description 197
230000003612 virological effect Effects 0.000 title claims abstract description 38
239000000463 material Substances 0.000 title claims abstract description 30
201000006417 multiple sclerosis Diseases 0.000 title claims description 121
239000012634 fragment Substances 0.000 title claims description 90
230000000295 complement effect Effects 0.000 claims abstract description 30
239000000178 monomer Substances 0.000 claims abstract description 22
108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 16
108090000765 processed proteins & peptides Proteins 0.000 claims description 146
108020004635 Complementary DNA Proteins 0.000 claims description 117
238000000034 method Methods 0.000 claims description 109
102000004196 processed proteins & peptides Human genes 0.000 claims description 67
230000003321 amplification Effects 0.000 claims description 65
238000003199 nucleic acid amplification method Methods 0.000 claims description 65
241000700605 Viruses Species 0.000 claims description 64
210000002966 serum Anatomy 0.000 claims description 58
108020004414 DNA Proteins 0.000 claims description 53
108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 51
239000000203 mixture Substances 0.000 claims description 44
239000000523 sample Substances 0.000 claims description 43
230000001717 pathogenic effect Effects 0.000 claims description 39
229920001184 polypeptide Polymers 0.000 claims description 39
150000001413 amino acids Chemical class 0.000 claims description 36
108090000623 proteins and genes Proteins 0.000 claims description 32
239000003795 chemical substances by application Substances 0.000 claims description 29
238000001514 detection method Methods 0.000 claims description 29
230000000890 antigenic effect Effects 0.000 claims description 28
108700004029 pol Genes Proteins 0.000 claims description 27
108091034117 Oligonucleotide Proteins 0.000 claims description 24
239000012678 infectious agent Substances 0.000 claims description 24
238000009396 hybridization Methods 0.000 claims description 22
101150088264 pol gene Proteins 0.000 claims description 21
206010039073 rheumatoid arthritis Diseases 0.000 claims description 19
241000282414 Homo sapiens Species 0.000 claims description 17
210000004369 blood Anatomy 0.000 claims description 16
239000008280 blood Substances 0.000 claims description 16
239000003153 chemical reaction reagent Substances 0.000 claims description 15
108700004026 gag Genes Proteins 0.000 claims description 14
230000036961 partial effect Effects 0.000 claims description 13
108700004025 env Genes Proteins 0.000 claims description 12
101150098622 gag gene Proteins 0.000 claims description 11
239000012472 biological sample Substances 0.000 claims description 10
230000001747 exhibiting effect Effects 0.000 claims description 10
108700026244 Open Reading Frames Proteins 0.000 claims description 9
101150030339 env gene Proteins 0.000 claims description 9
102000015636 Oligopeptides Human genes 0.000 claims description 8
108010038807 Oligopeptides Proteins 0.000 claims description 8
230000001225 therapeutic effect Effects 0.000 claims description 8
102000040430 polynucleotide Human genes 0.000 claims description 7
108091033319 polynucleotide Proteins 0.000 claims description 7
239000002157 polynucleotide Substances 0.000 claims description 7
230000000069 prophylactic effect Effects 0.000 claims description 6
230000002860 competitive effect Effects 0.000 claims description 5
230000002401 inhibitory effect Effects 0.000 claims description 5
230000010076 replication Effects 0.000 claims description 5
241001465754 Metazoa Species 0.000 claims description 4
108020004711 Nucleic Acid Probes Proteins 0.000 claims description 4
230000008105 immune reaction Effects 0.000 claims description 4
239000002853 nucleic acid probe Substances 0.000 claims description 4
108020004394 Complementary RNA Proteins 0.000 claims description 3
210000001175 cerebrospinal fluid Anatomy 0.000 claims description 3
230000001900 immune effect Effects 0.000 claims description 3
230000002163 immunogen Effects 0.000 claims description 3
239000007787 solid Substances 0.000 claims description 3
229940124447 delivery agent Drugs 0.000 claims description 2
230000028993 immune response Effects 0.000 claims description 2
238000006116 polymerization reaction Methods 0.000 claims description 2
229960005486 vaccine Drugs 0.000 claims description 2
239000003446 ligand Substances 0.000 claims 3
230000001024 immunotherapeutic effect Effects 0.000 claims 2
239000007788 liquid Substances 0.000 claims 1
238000010804 cDNA synthesis Methods 0.000 description 122
239000002299 complementary DNA Substances 0.000 description 113
238000012163 sequencing technique Methods 0.000 description 85
238000003752 polymerase chain reaction Methods 0.000 description 76
241001430294 unidentified retrovirus Species 0.000 description 48
239000000047 product Substances 0.000 description 44
230000001177 retroviral effect Effects 0.000 description 44
238000006243 chemical reaction Methods 0.000 description 40
102100034343 Integrase Human genes 0.000 description 39
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 39
239000013612 plasmid Substances 0.000 description 36
239000000243 solution Substances 0.000 description 34
229940024606 amino acid Drugs 0.000 description 33
210000002845 virion Anatomy 0.000 description 31
230000000694 effects Effects 0.000 description 29
238000010367 cloning Methods 0.000 description 28
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 28
150000007523 nucleic acids Chemical class 0.000 description 27
238000012360 testing method Methods 0.000 description 23
239000000872 buffer Substances 0.000 description 22
102000039446 nucleic acids Human genes 0.000 description 22
108020004707 nucleic acids Proteins 0.000 description 22
208000015181 infectious disease Diseases 0.000 description 20
239000012153 distilled water Substances 0.000 description 19
238000012408 PCR amplification Methods 0.000 description 18
238000003786 synthesis reaction Methods 0.000 description 17
210000002381 plasma Anatomy 0.000 description 16
238000003757 reverse transcription PCR Methods 0.000 description 16
239000011543 agarose gel Substances 0.000 description 14
239000002777 nucleoside Substances 0.000 description 14
150000003833 nucleoside derivatives Chemical class 0.000 description 14
238000002965 ELISA Methods 0.000 description 13
125000003275 alpha amino acid group Chemical group 0.000 description 13
230000015572 biosynthetic process Effects 0.000 description 13
101100224485 Arabidopsis thaliana POL2B gene Proteins 0.000 description 12
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
101100170950 Methanocella arvoryzae (strain DSM 22066 / NBRC 105507 / MRE50) polC gene Proteins 0.000 description 12
239000013642 negative control Substances 0.000 description 12
239000002245 particle Substances 0.000 description 12
238000002360 preparation method Methods 0.000 description 12
238000004458 analytical method Methods 0.000 description 11
210000004027 cell Anatomy 0.000 description 11
238000010790 dilution Methods 0.000 description 11
239000012895 dilution Substances 0.000 description 11
239000006228 supernatant Substances 0.000 description 11
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 10
241000894006 Bacteria Species 0.000 description 10
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 10
230000003287 optical effect Effects 0.000 description 10
230000007420 reactivation Effects 0.000 description 10
102000016911 Deoxyribonucleases Human genes 0.000 description 9
108010053770 Deoxyribonucleases Proteins 0.000 description 9
KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 9
229930006000 Sucrose Natural products 0.000 description 9
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 9
239000000853 adhesive Substances 0.000 description 9
230000001070 adhesive effect Effects 0.000 description 9
239000000356 contaminant Substances 0.000 description 9
239000000499 gel Substances 0.000 description 9
239000002244 precipitate Substances 0.000 description 9
239000005720 sucrose Substances 0.000 description 9
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
108090000790 Enzymes Proteins 0.000 description 8
239000012228 culture supernatant Substances 0.000 description 8
230000002950 deficient Effects 0.000 description 8
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 8
229960005542 ethidium bromide Drugs 0.000 description 8
210000004698 lymphocyte Anatomy 0.000 description 8
102000004169 proteins and genes Human genes 0.000 description 8
238000000746 purification Methods 0.000 description 8
239000011347 resin Substances 0.000 description 8
229920005989 resin Polymers 0.000 description 8
108091008146 restriction endonucleases Proteins 0.000 description 8
102000004190 Enzymes Human genes 0.000 description 7
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 7
239000000427 antigen Substances 0.000 description 7
102000036639 antigens Human genes 0.000 description 7
108091007433 antigens Proteins 0.000 description 7
201000010099 disease Diseases 0.000 description 7
238000004519 manufacturing process Methods 0.000 description 7
230000004048 modification Effects 0.000 description 7
238000012986 modification Methods 0.000 description 7
239000012071 phase Substances 0.000 description 7
230000008569 process Effects 0.000 description 7
238000010186 staining Methods 0.000 description 7
102000040650 (ribonucleotides)n+m Human genes 0.000 description 6
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
229930024421 Adenine Natural products 0.000 description 6
241000283707 Capra Species 0.000 description 6
108091035707 Consensus sequence Proteins 0.000 description 6
QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 6
102000003960 Ligases Human genes 0.000 description 6
108090000364 Ligases Proteins 0.000 description 6
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 6
108010006785 Taq Polymerase Proteins 0.000 description 6
229960000643 adenine Drugs 0.000 description 6
GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical group N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 6
238000003745 diagnosis Methods 0.000 description 6
238000000605 extraction Methods 0.000 description 6
230000003053 immunization Effects 0.000 description 6
238000002649 immunization Methods 0.000 description 6
238000011534 incubation Methods 0.000 description 6
230000002458 infectious effect Effects 0.000 description 6
239000013610 patient sample Substances 0.000 description 6
230000006798 recombination Effects 0.000 description 6
238000010839 reverse transcription Methods 0.000 description 6
239000000126 substance Substances 0.000 description 6
238000005406 washing Methods 0.000 description 6
108020004437 Endogenous Retroviruses Proteins 0.000 description 5
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 5
238000013459 approach Methods 0.000 description 5
-1 aryl phosphonate Chemical compound 0.000 description 5
238000003556 assay Methods 0.000 description 5
238000007796 conventional method Methods 0.000 description 5
238000005538 encapsulation Methods 0.000 description 5
239000012528 membrane Substances 0.000 description 5
QPJSUIGXIBEQAC-UHFFFAOYSA-N n-(2,4-dichloro-5-propan-2-yloxyphenyl)acetamide Chemical compound CC(C)OC1=CC(NC(C)=O)=C(Cl)C=C1Cl QPJSUIGXIBEQAC-UHFFFAOYSA-N 0.000 description 5
102000013415 peroxidase activity proteins Human genes 0.000 description 5
108040007629 peroxidase activity proteins Proteins 0.000 description 5
238000005215 recombination Methods 0.000 description 5
239000001632 sodium acetate Substances 0.000 description 5
239000000758 substrate Substances 0.000 description 5
208000024891 symptom Diseases 0.000 description 5
MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 4
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
241000701044 Human gammaherpesvirus 4 Species 0.000 description 4
108091005804 Peptidases Proteins 0.000 description 4
239000004365 Protease Substances 0.000 description 4
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 4
108020000999 Viral RNA Proteins 0.000 description 4
RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 4
210000003719 b-lymphocyte Anatomy 0.000 description 4
239000012148 binding buffer Substances 0.000 description 4
239000013060 biological fluid Substances 0.000 description 4
239000000969 carrier Substances 0.000 description 4
238000010828 elution Methods 0.000 description 4
230000036449 good health Effects 0.000 description 4
PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 4
230000004807 localization Effects 0.000 description 4
230000000926 neurological effect Effects 0.000 description 4
230000007170 pathology Effects 0.000 description 4
229920000136 polysorbate Polymers 0.000 description 4
235000019419 proteases Nutrition 0.000 description 4
125000006239 protecting group Chemical group 0.000 description 4
230000003362 replicative effect Effects 0.000 description 4
230000004044 response Effects 0.000 description 4
230000002441 reversible effect Effects 0.000 description 4
235000017281 sodium acetate Nutrition 0.000 description 4
241000894007 species Species 0.000 description 4
230000002269 spontaneous effect Effects 0.000 description 4
238000003860 storage Methods 0.000 description 4
QAPSNMNOIOSXSQ-YNEHKIRRSA-N 1-[(2r,4s,5r)-4-[tert-butyl(dimethyl)silyl]oxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O[Si](C)(C)C(C)(C)C)C1 QAPSNMNOIOSXSQ-YNEHKIRRSA-N 0.000 description 3
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 3
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
241001484259 Lacuna Species 0.000 description 3
102000007079 Peptide Fragments Human genes 0.000 description 3
108010033276 Peptide Fragments Proteins 0.000 description 3
238000002123 RNA extraction Methods 0.000 description 3
239000007983 Tris buffer Substances 0.000 description 3
230000009471 action Effects 0.000 description 3
230000001413 cellular effect Effects 0.000 description 3
238000000546 chi-square test Methods 0.000 description 3
238000012790 confirmation Methods 0.000 description 3
230000008878 coupling Effects 0.000 description 3
238000010168 coupling process Methods 0.000 description 3
238000005859 coupling reaction Methods 0.000 description 3
SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 3
SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 3
238000010586 diagram Methods 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
238000003780 insertion Methods 0.000 description 3
230000037431 insertion Effects 0.000 description 3
230000003993 interaction Effects 0.000 description 3
150000002500 ions Chemical class 0.000 description 3
238000007857 nested PCR Methods 0.000 description 3
230000001575 pathological effect Effects 0.000 description 3
238000011160 research Methods 0.000 description 3
238000000926 separation method Methods 0.000 description 3
230000008685 targeting Effects 0.000 description 3
238000013519 translation Methods 0.000 description 3
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
230000003442 weekly effect Effects 0.000 description 3
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical class C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 2
MXHRCPNRJAMMIM-SHYZEUOFSA-N 2'-deoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-SHYZEUOFSA-N 0.000 description 2
ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical group OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 2
229920000936 Agarose Polymers 0.000 description 2
229920002527 Glycogen Polymers 0.000 description 2
241001622557 Hesperia Species 0.000 description 2
241000282412 Homo Species 0.000 description 2
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
239000004793 Polystyrene Substances 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
238000002105 Southern blotting Methods 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
108020005202 Viral DNA Proteins 0.000 description 2
230000001594 aberrant effect Effects 0.000 description 2
239000002250 absorbent Substances 0.000 description 2
230000002745 absorbent Effects 0.000 description 2
230000021736 acetylation Effects 0.000 description 2
238000006640 acetylation reaction Methods 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
239000008346 aqueous phase Substances 0.000 description 2
230000001363 autoimmune Effects 0.000 description 2
229920001222 biopolymer Polymers 0.000 description 2
UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 2
238000004364 calculation method Methods 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
210000003169 central nervous system Anatomy 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
238000003776 cleavage reaction Methods 0.000 description 2
239000000470 constituent Substances 0.000 description 2
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 2
HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 2
230000006378 damage Effects 0.000 description 2
230000003412 degenerative effect Effects 0.000 description 2
238000012217 deletion Methods 0.000 description 2
230000037430 deletion Effects 0.000 description 2
MXHRCPNRJAMMIM-UHFFFAOYSA-N desoxyuridine Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-UHFFFAOYSA-N 0.000 description 2
238000011161 development Methods 0.000 description 2
230000029087 digestion Effects 0.000 description 2
238000006073 displacement reaction Methods 0.000 description 2
230000009977 dual effect Effects 0.000 description 2
238000001962 electrophoresis Methods 0.000 description 2
230000002255 enzymatic effect Effects 0.000 description 2
239000011536 extraction buffer Substances 0.000 description 2
238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 2
230000006870 function Effects 0.000 description 2
229940096919 glycogen Drugs 0.000 description 2
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
210000000987 immune system Anatomy 0.000 description 2
230000000984 immunochemical effect Effects 0.000 description 2
230000006698 induction Effects 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
230000003902 lesion Effects 0.000 description 2
239000003550 marker Substances 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
238000005259 measurement Methods 0.000 description 2
UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 2
230000035772 mutation Effects 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
230000007918 pathogenicity Effects 0.000 description 2
238000010647 peptide synthesis reaction Methods 0.000 description 2
125000001151 peptidyl group Chemical group 0.000 description 2
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
238000013492 plasmid preparation Methods 0.000 description 2
239000004033 plastic Substances 0.000 description 2
229920002223 polystyrene Polymers 0.000 description 2
230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
230000009257 reactivity Effects 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
230000000717 retained effect Effects 0.000 description 2
230000000405 serological effect Effects 0.000 description 2
238000004904 shortening Methods 0.000 description 2
239000002904 solvent Substances 0.000 description 2
238000001179 sorption measurement Methods 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
238000005199 ultracentrifugation Methods 0.000 description 2
238000009423 ventilation Methods 0.000 description 2
125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 1
LUCHPKXVUGJYGU-XLPZGREQSA-N 5-methyl-2'-deoxycytidine Chemical compound O=C1N=C(N)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 LUCHPKXVUGJYGU-XLPZGREQSA-N 0.000 description 1
XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 1
MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 description 1
ZXKNLCPUNZPFGY-LEWSCRJBSA-N Ala-Tyr-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N2CCC[C@@H]2C(=O)O)N ZXKNLCPUNZPFGY-LEWSCRJBSA-N 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
101710191958 Amino-acid acetyltransferase Proteins 0.000 description 1
102100023167 Argininosuccinate lyase Human genes 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
206010051290 Central nervous system lesion Diseases 0.000 description 1
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
229930105110 Cyclosporin A Natural products 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
238000007400 DNA extraction Methods 0.000 description 1
108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
102100029764 DNA-directed DNA/RNA polymerase mu Human genes 0.000 description 1
208000016192 Demyelinating disease Diseases 0.000 description 1
101100224481 Dictyostelium discoideum pole gene Proteins 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
108010067770 Endopeptidase K Proteins 0.000 description 1
QTANTQQOYSUMLC-UHFFFAOYSA-O Ethidium cation Chemical compound C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 QTANTQQOYSUMLC-UHFFFAOYSA-O 0.000 description 1
108091007413 Extracellular RNA Proteins 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
241000700721 Hepatitis B virus Species 0.000 description 1
PGXZHYYGOPKYKM-IHRRRGAJSA-N His-Pro-Lys Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CC2=CN=CN2)N)C(=O)N[C@@H](CCCCN)C(=O)O PGXZHYYGOPKYKM-IHRRRGAJSA-N 0.000 description 1
101000912957 Homo sapiens Protein DEK Proteins 0.000 description 1
241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
229930010555 Inosine Natural products 0.000 description 1
UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
241000813323 Maize streak Reunion virus Species 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
241000237536 Mytilus edulis Species 0.000 description 1
208000008457 Neurologic Manifestations Diseases 0.000 description 1
206010060860 Neurological symptom Diseases 0.000 description 1
238000000636 Northern blotting Methods 0.000 description 1
238000002944 PCR assay Methods 0.000 description 1
101150102573 PCR1 gene Proteins 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
101150110488 POL2 gene Proteins 0.000 description 1
241000609499 Palicourea Species 0.000 description 1
239000004952 Polyamide Substances 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
239000013614 RNA sample Substances 0.000 description 1
PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
OEXWWDYOBBQCKD-UHFFFAOYSA-N SSSSSS Chemical compound SSSSSS OEXWWDYOBBQCKD-UHFFFAOYSA-N 0.000 description 1
101100365193 Schizosaccharomyces pombe (strain 972 / ATCC 24843) sec73 gene Proteins 0.000 description 1
238000012300 Sequence Analysis Methods 0.000 description 1
RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
108091023040 Transcription factor Proteins 0.000 description 1
239000007984 Tris EDTA buffer Substances 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000002253 acid Substances 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000004913 activation Effects 0.000 description 1
238000001994 activation Methods 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
150000001412 amines Chemical group 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
229960000723 ampicillin Drugs 0.000 description 1
230000005875 antibody response Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
230000002238 attenuated effect Effects 0.000 description 1
239000012620 biological material Substances 0.000 description 1
229960002685 biotin Drugs 0.000 description 1
235000020958 biotin Nutrition 0.000 description 1
239000011616 biotin Substances 0.000 description 1
230000008499 blood brain barrier function Effects 0.000 description 1
238000010241 blood sampling Methods 0.000 description 1
210000001218 blood-brain barrier Anatomy 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
229950004398 broxuridine Drugs 0.000 description 1
239000008366 buffered solution Substances 0.000 description 1
238000010805 cDNA synthesis kit Methods 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
230000021523 carboxylation Effects 0.000 description 1
238000006473 carboxylation reaction Methods 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
108091092328 cellular RNA Proteins 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
230000008859 change Effects 0.000 description 1
238000012411 cloning technique Methods 0.000 description 1
230000006690 co-activation Effects 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
239000013068 control sample Substances 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
229940104302 cytosine Drugs 0.000 description 1
NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
230000006735 deficit Effects 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
AQEFLFZSWDEAIP-UHFFFAOYSA-N di-tert-butyl ether Chemical compound CC(C)(C)OC(C)(C)C AQEFLFZSWDEAIP-UHFFFAOYSA-N 0.000 description 1
238000002405 diagnostic procedure Methods 0.000 description 1
125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
239000001177 diphosphate Substances 0.000 description 1
XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
235000011180 diphosphates Nutrition 0.000 description 1
231100000676 disease causative agent Toxicity 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
238000006872 enzymatic polymerization reaction Methods 0.000 description 1
230000032050 esterification Effects 0.000 description 1
238000005886 esterification reaction Methods 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
210000004602 germ cell Anatomy 0.000 description 1
230000013595 glycosylation Effects 0.000 description 1
238000006206 glycosylation reaction Methods 0.000 description 1
ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
238000000265 homogenisation Methods 0.000 description 1
102000055418 human Dek Human genes 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
230000008676 import Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
230000001524 infective effect Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
208000014674 injury Diseases 0.000 description 1
229960003786 inosine Drugs 0.000 description 1
238000005342 ion exchange Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
229960000310 isoleucine Drugs 0.000 description 1
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
238000004811 liquid chromatography Methods 0.000 description 1
239000007791 liquid phase Substances 0.000 description 1
229910052943 magnesium sulfate Inorganic materials 0.000 description 1
235000019341 magnesium sulphate Nutrition 0.000 description 1
238000013507 mapping Methods 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
239000008267 milk Substances 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
235000020638 mussel Nutrition 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
239000011824 nuclear material Substances 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
244000045947 parasite Species 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
210000005259 peripheral blood Anatomy 0.000 description 1
239000011886 peripheral blood Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
239000008055 phosphate buffer solution Substances 0.000 description 1
229920002647 polyamide Polymers 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
239000013641 positive control Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
238000002953 preparative HPLC Methods 0.000 description 1
238000004262 preparative liquid chromatography Methods 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
238000004393 prognosis Methods 0.000 description 1
108010090894 prolylleucine Proteins 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
244000000066 protist pathogen Species 0.000 description 1
238000011002 quantification Methods 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
239000012429 reaction media Substances 0.000 description 1
125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
230000007017 scission Effects 0.000 description 1
238000012216 screening Methods 0.000 description 1
239000013049 sediment Substances 0.000 description 1
238000009589 serological test Methods 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
238000010532 solid phase synthesis reaction Methods 0.000 description 1
238000011895 specific detection Methods 0.000 description 1
238000002798 spectrophotometry method Methods 0.000 description 1
238000005728 strengthening Methods 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
150000003573 thiols Chemical group 0.000 description 1
229940113082 thymine Drugs 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
230000005758 transcription activity Effects 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
230000009466 transformation Effects 0.000 description 1
GEUFMGZEFYJAEJ-UHFFFAOYSA-N tris(2-methylpropyl)silicon Chemical compound CC(C)C[Si](CC(C)C)CC(C)C GEUFMGZEFYJAEJ-UHFFFAOYSA-N 0.000 description 1
125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
241001529453 unidentified herpesvirus Species 0.000 description 1
229940035893 uracil Drugs 0.000 description 1
108700026220 vif Genes Proteins 0.000 description 1
230000007419 viral reactivation Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/702—Specific hybridization probes for retroviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Wood Science & Technology (AREA)
Genetics & Genomics (AREA)
Immunology (AREA)
Zoology (AREA)
Bioinformatics & Cheminformatics (AREA)
Virology (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Analytical Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Physics & Mathematics (AREA)
General Engineering & Computer Science (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Rheumatology (AREA)
Pathology (AREA)
Gastroenterology & Hepatology (AREA)
Communicable Diseases (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Oncology (AREA)
Physical Education & Sports Medicine (AREA)
Neurology (AREA)
Orthopedic Medicine & Surgery (AREA)
Biomedical Technology (AREA)

BG101355A 1995-08-03 1997-03-25 Вирусен материал и нуклеотидни фрагменти, свързани с диагностика, профилактика и лечение на мултиплената склероза BG62977B1 (bg)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR9509643A FR2737500B1 (fr)	1995-08-03	1995-08-03	Materiel viral et fragments nucleotidiques associes a la sclerose en plaques, a des fins de diagnostic, prophylactiques et therapeutiques
PCT/FR1996/001244 WO1997006260A1 (fr)	1995-08-03	1996-08-02	Materiel viral et fragments nucleotidiques associes a la sclerose en plaques, a des fins de diagnostic, prophylactiques et therapeutiques

Publications (2)

Publication Number	Publication Date
BG101355A BG101355A (en)	1997-12-30
BG62977B1 true BG62977B1 (bg)	2000-12-29

Family

ID=9481811

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG101355A BG62977B1 (bg)	1995-08-03	1997-03-25	Вирусен материал и нуклеотидни фрагменти, свързани с диагностика, профилактика и лечение на мултиплената склероза

Country Status (19)

Country	Link
US (4)	US6001987A (2)
EP (2)	EP0789077B1 (2)
JP (2)	JP4444372B2 (2)
AT (2)	ATE374252T1 (2)
AU (1)	AU730080B2 (2)
BG (1)	BG62977B1 (2)
BR (1)	BR9606566A (2)
CA (1)	CA2201282C (2)
CZ (1)	CZ135797A3 (2)
DE (1)	DE69637264T2 (2)
ES (2)	ES2293645T3 (2)
FR (1)	FR2737500B1 (2)
HU (1)	HUP9900425A3 (2)
IS (1)	IS4455A (2)
NO (1)	NO971493L (2)
NZ (1)	NZ316080A (2)
PL (1)	PL319512A1 (2)
SK (1)	SK56797A3 (2)
WO (1)	WO1997006260A1 (2)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2737500B1 (fr) *	1995-08-03	1997-08-29	Bio Merieux	Materiel viral et fragments nucleotidiques associes a la sclerose en plaques, a des fins de diagnostic, prophylactiques et therapeutiques
US7241876B2 (en)	1996-01-11	2007-07-10	Corixa Corporation	Compositions and methods for the therapy and diagnosis of breast cancer
ATE471150T1 (de) *	1996-03-26	2010-07-15	Kopreski Michael S	Methoden aus plasma oder serum extrahierte extrazelluraere rna zur diagnoseüberwachung oder evaluation von krebs verwenden
US8043835B1 (en)	1996-03-26	2011-10-25	Oncomedx, Inc.	Methods for detecting and monitoring cancer using extracellular RNA
US7785842B2 (en) *	1996-03-26	2010-08-31	Oncomedx, Inc.	Comparative analysis of extracellular RNA species
US6759217B2 (en) *	1996-03-26	2004-07-06	Oncomedx, Inc.	Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer
JP4044142B2 (ja) *	1996-10-04	2008-02-06	ビー．アーノビッツ，ハワード	核酸の診断検出
EP0942987B1 (en) *	1996-11-26	2009-08-19	Bio Merieux	Viral material and nucleotide fragments associated with multiple sclerosis, for diagnostic, prophylactic and therapeutic purposes
US20070009934A1 (en) *	1997-03-14	2007-01-11	Kopreski Michael S	Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer
US8440396B2 (en) *	1997-03-14	2013-05-14	Oncomedx, Inc.	Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer
FR2762601B3 (fr) *	1997-04-29	1999-06-04	Bio Merieux	Polypeptide capable de reagir avec les anticorps de patients atteints de sclerose en plaques et utilisations
FR2762600B1 (fr) *	1997-04-29	1999-11-05	Bio Merieux	Polypeptide capable de reagir avec les anticorps de patients atteints de sclerose en plaques et utlisations
US20040176314A1 (en) *	1997-07-07	2004-09-09	Bio Merieux	Endogenetic retroviral sequences, associated with autoimmune diseases or with pregnancy disorders
FR2765588A1 (fr)	1997-07-07	1999-01-08	Bio Merieux	Materiel nucleique retroviral et fragments nucleotidiques notamment associes a la sclerose en plaques et/ou la polyarthrite rhumatoide, a des fins de diagnostic, prophylactiques et therapeutiques
ATE346153T1 (de) *	1997-07-07	2006-12-15	Bio Merieux	Endogene retrovirale sequenzen, verwandten mit auto-immune krankheiten oder mit schwangerschaftsstörungen
EP1068361A1 (en) *	1998-04-08	2001-01-17	MS Research A/S	Diagnosis of multiple sclerosis and other demyelinating diseases
FR2780069B1 (fr) *	1998-06-23	2002-06-28	Inst Nat Sante Rech Med	Famille de sequences nucleiques et de sequences proteiques deduites presentant des motifs retroviraux endogenes humains et leurs applications
US20060204989A1 (en) *	1998-09-22	2006-09-14	Kopreski Michael S	Comparative analysis of extracellular RNA species
US8163524B2 (en) *	1998-09-22	2012-04-24	Oncomedx, Inc.	Comparative analysis of extracellular RNA species
US20090233276A1 (en) *	1998-09-22	2009-09-17	Oncomedx, Inc.	Method Enabling the Use of Extracellular Ribonucleic Acid (RNA) Extracted from Plasma or Serum to Detect, Monitor or Evaluate Cancer or Premalignant Conditions
FR2788784A1 (fr) *	1999-01-21	2000-07-28	Bio Merieux	Fragment nucleique endogene associe a une maladie auto-immune, procede de marquage et reactif
EP1029917A1 (en)	1999-02-15	2000-08-23	Bio Merieux	The LTR region of MSRV-1 and the proteins it encodes, and probes and methods for detecting MSRV-1 retrovirus
WO2001014564A2 (en) *	1999-08-20	2001-03-01	Curagen Corporation	Polynucleotides expressed in activated t-lymphocytes and proteins encoded thereby
DE10012875B4 (de) *	2000-03-16	2004-04-01	Infineon Technologies Ag	Mobilfunkempfänger
CA2403815A1 (en) *	2000-03-21	2001-09-27	Ms Research A/S	An infective endogenous retrovirus in association with demyelinating diseases e.g. multiple sclerosis
DE60239470D1 (de) *	2001-07-25	2011-04-28	Oncomedx Inc	Verfahren zur bewertung pathologischer krankheitszustände unter verwendung extrazellulärer rna
US20100159464A1 (en) *	2001-11-05	2010-06-24	Oncomedx, Inc.	Method for Detection of DNA Methyltransferase RNA in Plasma and Serum
US20030104454A1 (en) *	2001-11-05	2003-06-05	Kopreski Michael S.	Method for detection of DNA methyltransferase RNA in plasma and serum
US20090136942A1 (en) *	2007-09-18	2009-05-28	Oncomedx, Inc.	Analysis of Extracellular RNA
US8680065B2 (en) *	2008-09-11	2014-03-25	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Oligonucleotides of human endogenous retrovirus 9 (ERV-9) long terminal repeat (LTR) and methods of use

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5871996A (en)	1994-02-04	1999-02-16	Bio Merieux	Retrovirus agents MSRV1 and MSRV2 associated with multiple sclerosis
WO1980000412A1 (en) *	1978-08-24	1980-03-20	N Gilmour	Pasteurellosis vaccines
US4311686A (en) *	1979-04-30	1982-01-19	The Immunology Development Corporation	Methodology for the immunodiagnosis of multiple sclerosis and/or malignant diseases from blood sample analysis
US4396600A (en) *	1980-12-18	1983-08-02	Gus Gallucci	Adult schistosome worm-derived antigenic substance and method of obtaining same
US4388298A (en) *	1982-07-14	1983-06-14	The United States Of America As Represented By The Secretary Of Agriculture	Propagation of hemorrhagic enteritis virus in a turkey cell line and vaccine produced
GB8324800D0 (en) *	1983-09-15	1983-10-19	Pasteur Institut	Antigens
US4520113A (en) *	1984-04-23	1985-05-28	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Serological detection of antibodies to HTLV-III in sera of patients with AIDS and pre-AIDS conditions
US4647773A (en) *	1984-04-23	1987-03-03	The United States Of America As Represented By The Department Of Health And Human Services	Method of continuous production of retroviruses (HTLV-III) from patients with AIDS and pre-AIDS
NZ218050A (en) *	1985-11-13	1989-05-29	Wistar Inst	Test for the presence of htlv-1v
US4900553A (en) *	1987-09-11	1990-02-13	Case Western Reserve University	Method of reducing glial scar formation and promoting axon and blood vessel growth and/or regeneration through the use of activated immature astrocytes
EP0326395A2 (en) *	1988-01-29	1989-08-02	City Of Hope	Method of detecting and identifying certain viral sequences
FR2651581B1 (fr) *	1989-09-06	1994-05-13	Centre Nal Recherc Scientifique	Moyens pour le diagnostic de neuropathies demyelinisantes, en particulier de la sclerose en plaques.
US5219837A (en) *	1990-06-21	1993-06-15	Trustees Of The University Of Pennsylvania	Method of stimulating myelination of cells
US5158976A (en) *	1990-10-29	1992-10-27	The Children's Medical Center Corporation	Controlling glutamine/glutamate related neuronal injury
DE69233158T2 (de) *	1991-03-07	2004-05-13	Connaught Technology Corp., Greenville	Gentechnologisch hergestellter stamm für impfstoffe
DK173091D0 (da) *	1991-10-11	1991-10-11	Schleroseforeningen The Danish	Biologisk materiale
FR2689521B1 (fr) *	1992-04-03	1996-07-19	Bio Merieux	Procede d'obtention et maintien d'une culture cellulaire viable, infectee par un virus associe a la sclerose en plaques, et produits biologiques derives de ladite culture.
FR2689520B1 (fr)	1992-04-03	1996-07-19	Bio Merieux	Procede et milieu de culture pour l'obtention de cellules infectees par un virus associe a la sclerose en plaques.
DK0642585T3 (da) *	1992-05-18	2006-05-15	Genentech Inc	Aktiviering af oligomeriserende receptorer ved anvendelse af fusionerede receptorligander
GB9310657D0 (en) *	1993-05-24	1993-07-07	Univ London	Retrovirus
US5580766A (en) *	1994-01-14	1996-12-03	Alexion Pharmaceuticals, Inc.	Retroviral vector particles for transducing non-proliferating cells
US5691147A (en) *	1994-06-02	1997-11-25	Mitotix, Inc.	CDK4 binding assay
US5710037A (en) *	1994-06-10	1998-01-20	The United States Of America As Represented By The Department Of Health And Human Services	Retroviral vector particles
FR2731356B1 (fr) *	1995-03-09	1997-04-30	Bio Merieux	Virus msrv-1 et agent pathogene et/ou infectant msrv-2 associes a la polyarthrite rhumatoide
FR2737500B1 (fr) *	1995-08-03	1997-08-29	Bio Merieux	Materiel viral et fragments nucleotidiques associes a la sclerose en plaques, a des fins de diagnostic, prophylactiques et therapeutiques

1995
- 1995-08-03 FR FR9509643A patent/FR2737500B1/fr not_active Expired - Fee Related
1996
- 1996-08-02 AU AU68232/96A patent/AU730080B2/en not_active Ceased
- 1996-08-02 DE DE69637264T patent/DE69637264T2/de not_active Expired - Lifetime
- 1996-08-02 EP EP96420265A patent/EP0789077B1/fr not_active Expired - Lifetime
- 1996-08-02 WO PCT/FR1996/001244 patent/WO1997006260A1/fr not_active Ceased
- 1996-08-02 ES ES96420265T patent/ES2293645T3/es not_active Expired - Lifetime
- 1996-08-02 CZ CZ971357A patent/CZ135797A3/cs unknown
- 1996-08-02 EP EP07018564A patent/EP1916304B1/fr not_active Expired - Lifetime
- 1996-08-02 CA CA2201282A patent/CA2201282C/fr not_active Expired - Lifetime
- 1996-08-02 SK SK567-97A patent/SK56797A3/sk unknown
- 1996-08-02 JP JP50817997A patent/JP4444372B2/ja not_active Expired - Lifetime
- 1996-08-02 AT AT96420265T patent/ATE374252T1/de not_active IP Right Cessation
- 1996-08-02 HU HU9900425A patent/HUP9900425A3/hu unknown
- 1996-08-02 AT AT07018564T patent/ATE541933T1/de active
- 1996-08-02 PL PL96319512A patent/PL319512A1/xx unknown
- 1996-08-02 BR BR9606566A patent/BR9606566A/pt unknown
- 1996-08-02 US US08/691,563 patent/US6001987A/en not_active Expired - Lifetime
- 1996-08-02 ES ES07018564T patent/ES2379011T3/es not_active Expired - Lifetime
1997
- 1997-03-25 BG BG101355A patent/BG62977B1/bg unknown
- 1997-03-26 IS IS4455A patent/IS4455A/is unknown
- 1997-03-27 NZ NZ316080A patent/NZ316080A/en unknown
- 1997-04-02 NO NO971493A patent/NO971493L/no not_active Application Discontinuation
1999
- 1999-08-16 US US09/374,766 patent/US6579526B1/en not_active Expired - Lifetime
2003
- 2003-05-07 US US10/430,442 patent/US20030186391A1/en not_active Abandoned
2006
- 2006-08-08 US US11/463,109 patent/US7932350B2/en not_active Expired - Fee Related
2009
- 2009-11-20 JP JP2009265658A patent/JP5143814B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
CA2201282A1 (fr)	1997-02-20
FR2737500B1 (fr)	1997-08-29
HUP9900425A2 (hu)	1999-05-28
AU730080B2 (en)	2001-02-22
EP0789077B1 (fr)	2007-09-26
PL319512A1 (en)	1997-08-18
JP5143814B2 (ja)	2013-02-13
IS4455A (is)	1997-03-26
WO1997006260A1 (fr)	1997-02-20
EP1916304A3 (fr)	2008-05-07
JP2010047604A (ja)	2010-03-04
ATE541933T1 (de)	2012-02-15
NO971493L (no)	1997-06-03
US20030186391A1 (en)	2003-10-02
JP4444372B2 (ja)	2010-03-31
AU6823296A (en)	1997-03-05
US6001987A (en)	1999-12-14
US6579526B1 (en)	2003-06-17
BR9606566A (pt)	1997-12-30
BG101355A (en)	1997-12-30
DE69637264T2 (de)	2008-06-26
FR2737500A1 (fr)	1997-02-07
EP1916304A2 (fr)	2008-04-30
EP0789077A1 (fr)	1997-08-13
ATE374252T1 (de)	2007-10-15
CA2201282C (fr)	2013-04-02
ES2293645T3 (es)	2008-03-16
HUP9900425A3 (en)	1999-11-29
JPH11502416A (ja)	1999-03-02
ES2379011T3 (es)	2012-04-19
NO971493D0 (no)	1997-04-02
EP1916304B1 (fr)	2012-01-18
CZ135797A3 (cs)	1998-06-17
US20070117189A1 (en)	2007-05-24
NZ316080A (en)	1999-04-29
DE69637264D1 (de)	2007-11-08
US7932350B2 (en)	2011-04-26
SK56797A3 (en)	1998-09-09

Publication	Publication Date	Title
BG62977B1 (bg)	2000-12-29	Вирусен материал и нуклеотидни фрагменти, свързани с диагностика, профилактика и лечение на мултиплената склероза
CA2272845C (en)	2010-01-12	Viral material and nucleotide fragments associated with multiple sclerosis, for diagnostic, prophylactic and therapeutic purposes
Haseltine et al.	1984	Structure of 3′ terminal region of type II human T lymphotropic virus: Evidence for new coding region
AU625174B2 (en)	1992-07-02	Hiv-2 virus variants
JP3428012B2 (ja)	2003-07-22	Ｈｉｖ―１、ｈｉｖ―２及びｓｉｖタイプのレトロウイルスのゲノムからのヌクレオチド配列、並びに、特に、これらのレトロウイルスのゲノムの増幅のため及びこれらのウイルスによる感染の「生体外」診断のためのこれらの配列の応用
JP3611856B2 (ja)	2005-01-19	多発性硬化症に関与するｍｓｒｖ１ウイルスおよびｍｓｒｖ２病因性及び／又は感染性の作因、核酸成分およびその応用
JP2569185B2 (ja)	1997-01-08	抗ｈｉｖ応答を喚起する合成抗原
CA2169603C (en)	2005-01-18	Retrovirus from the hiv group and its use
US6548635B1 (en)	2003-04-15	Retrovirus from the HIV type O and its use (MVP-2901/94)
JP2002515725A (ja)	2002-05-28	カポジ肉腫および腹膜後繊維腫症に関連するガンマヘルペスウイルスのｄｎａポリメラーゼ
JP4272264B2 (ja)	2009-06-03	診断予防及び治療的使用のための、特に多発性硬化症及び／又は慢性関節リウマチに関連した、レトロウイルス核材料及びヌクレオチドフラグメント